Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Finished Goods (2016 - 2025)

Historic Finished Goods for Ocular Therapeutix (OCUL) over the last 12 years, with Q4 2025 value amounting to $1.6 million.

  • Ocular Therapeutix's Finished Goods rose 2273.75% to $1.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.6 million, marking a year-over-year increase of 2273.75%. This contributed to the annual value of $1.6 million for FY2025, which is 2273.75% up from last year.
  • Ocular Therapeutix's Finished Goods amounted to $1.6 million in Q4 2025, which was up 2273.75% from $1.9 million recorded in Q3 2025.
  • Ocular Therapeutix's Finished Goods' 5-year high stood at $1.9 million during Q3 2025, with a 5-year trough of $257000.0 in Q4 2021.
  • Moreover, its 5-year median value for Finished Goods was $1.0 million (2023), whereas its average is $917900.0.
  • Per our database at Business Quant, Ocular Therapeutix's Finished Goods crashed by 6126.01% in 2021 and then soared by 19805.45% in 2022.
  • Ocular Therapeutix's Finished Goods (Quarter) stood at $257000.0 in 2021, then soared by 198.05% to $766000.0 in 2022, then grew by 29.37% to $991000.0 in 2023, then skyrocketed by 34.91% to $1.3 million in 2024, then rose by 22.74% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q4 2025, $1.9 million for Q3 2025, and $1.1 million during Q2 2025.